#BLAnswers | What are the prospects for the medium and the long term for Suven Pharmaceuticals?
You have clicked on a link which leaves THBL website, and you will be redirected to a third party website.THBL makes no representations nor has any supervision or control over the content, reliability or security of the third party website, nor shall THBL be liable for its use.
Suven Pharmaceuticals (₹332.3): After getting listed in early March this year, the stock of Suven Pharmaceuticals witnessed a downmove and recorded a fresh low at ₹87 (adjusted) in late March.
It now tests a crucial support at ₹320. A decline below this base can pull the stock down to ₹295 and then to ₹280 over the short term. Further plunge below ₹280 can drag the stock down to ₹240.
On the upside, a strong breakthrough above the immediate resistance level of ₹360 can reinforce the uptrend and take the stock northwards to ₹380 and then to ₹400 in the medium term.